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OBJECTIVES: The objective of this study was to assess
the compliance and treatment satisfaction with risperi-
done in a U.S. sample of patients with bipolar disorder.
METHODS: In June 2001, 573 persons reported being
diagnosed with bipolar disorder on a self-administered
questionnaire. Patients receiving risperidone were identi-
ﬁed and information on compliance and treatment satis-
faction was extracted. Satisfaction and compliance with
treatment were measured using the Drug Attitude 
Inventory (DAI) and a 5-point Likert scale. The satisfac-
tion scale ranges from not at all (1) to extremely satisﬁed
(5), while the DAI classiﬁes the patients in 3 groups, non-
compliant (-10 to 0), somewhat compliant (1 to 5), and
very compliant (6 to 10) with treatment. RESULTS:
Thirty-one (5.4%) of 573 patients with bipolar disorder
were receiving risperidone. The average length of treat-
ment was 33.1 (SD = 23.5) months. Twenty-three (73%)
of 31 patients reported being very or extremely (4 or 5)
satisﬁed with the medication, while only 4 patients (12%)
reported no or little satisfaction with treatment. The
majority of patients, 22 (68%), reported being very 
compliant with their treatment. CONCLUSION: In this
population of patients with bipolar disorder, patients
receiving risperidone appear to have a high satisfaction
with treatment and a high compliance rate.
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OBJECTIVE: Compliance plays a major role in chronic
conditions to help achieve a full course of therapy. All
chronic diseases have adherence to prescribed drug
therapy as obstacles to treatment. Potential consequences
of non-adherence include relapse, treatment resistance,
suicide, impairment of functioning (work, interpersonal)
and worsening of comorbid illnesses. All of these poten-
tial consequences can have a signiﬁcant economic burden
on the society. So we intended to evaluate the clinical efﬁ-
cacy of ﬂuoxetine 180mg (2 ¥ 90mg tablets) once a week
in ambulatory patients stabilized on Fluoxetine 40mg
daily. METHOD: Thirty patients stabilized on ﬂuoxetine
40mg daily were evaluated in a mirror image design.
They were switched to ﬂuoxetine 180mg (2 ¥ 90mg
tablets) once a week. Steady state serum drug concentra-
tion and Clinical Global Impression-Severity (CGI-S),
medication compliance and patient attitude survey were
obtained before and after the switch. RESULTS: Mean
age of the patients was 41.7 + 11.7 years, with 8 males
and all of them met DSM IV criteria for major depres-
sion. Mean duration of depression was 8 + 3 years. 
Fluoxetine/Norﬂuoxetine serum concentrations were 261
+ 185 and 295 + 206ng/ml (P = .21.). CGI-S was 2.5 +
0.7 and 2.6 + 0.7 before and after the switch. Compli-
ance before the switch was 73.6% before and 91% after
the switch. This difference was statistically signiﬁcant at 
p < 0.0001 (t = -7.8651, df = 29). 41% of the patients
strongly agreed that weekly dosing regimen was preferred
over daily regimen. CONCLUSION: Our evaluation 
indicates that once a week dosing is as equally clinically
efﬁcacious as a daily dose in the management of major
depression in our population of ambulatory patients. 
Signiﬁcant improvement in compliance can only have a
positive impact on the health outcome and costs.
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OBJECTIVES: To examine and describe gender differ-
ences in psychoactive medication treatment for AD/HD
in a population-based cohort. METHODS: Medical 
and school records of all children born (N = 5718) in
Rochester, MN 1976–1982 were reviewed to identify
those with AD/HD (N = 375). All psychoactive 
medications (psychostimulants [STIM], centrally acting 
alpha-adrenergic agonists [CAA] and/or tricyclic 
antidepressants [TCA]), doses prescribed, start and 
stop dates, and subtype of AD/HD clinical diagnosis 
were abstracted. Psychostimulant doses were converted 
to Methylphenidate Equivalent Units (MEU: 20mg
methylphenidate = 10mg dextroamphetamine = 10mg
amphetamine salts = 56.25mg pemoline). RESULTS:
Boys with AD/HD were more likely than girls to be
treated with STIM, either alone or in combination with
TCA and/or CAA (80.8% vs 69.1%, OR 1.9, 95% CI
1.1–3.2, p = 0.020). However, boys and girls were equally
likely to be treated with STIM alone (66.2% versus
63.8%, OR 1.1, 95% CI 0.7–1.8, p = 0.68). Mean age at
treatment onset was similar (boys 10.3 years, girls 10.7
years, p = 0.46). Median treatment duration was 34
months (mean = 42.0, SD = 37.1), with no gender differ-
ence. Median average daily dose of STIM was 21.3mg
MEU (mean = 24.4mg, SD = 11.0mg). Boys received 
signiﬁcantly higher average daily doses than girls (median
22.5 vs. 20.0mg MEU; p = 0.002). Treatment started 
signiﬁcantly earlier for combined (9.7 years) and 
hyperactive-impulsive subtypes (10.0 years) than for the
inattentive type (12.7 years). Treatment duration was 
signiﬁcantly longer for combined (40.5 months) than for
either hyperactive-impulsive (22.6 months) or inattentive
subtype (19.1 months). The gender differences in AD/HD
treatment described above could not be accounted for by
gender differences in AD/HD subtype. CONCLUSIONS:
Boys with AD/HD were more likely to be treated with
